- Home
- ABVC vs ICCC Comparison
ABVC vs ICCC Comparison
Compare ABVC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ICCC
- Stock Information
- Founded
- ABVC 2015
- ICCC 1982
- Country
- ABVC United States
- ICCC United States
- Employees
- ABVC N/A
- ICCC N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- ICCC Health Care
- Exchange
- ABVC Nasdaq
- ICCC Nasdaq
- Market Cap
- ABVC 52.1M
- ICCC 55.5M
- IPO Year
- ABVC N/A
- ICCC 1987
- Fundamental
- Price
- ABVC $2.84
- ICCC $6.31
- Analyst Decision
- ABVC
- ICCC
- Analyst Count
- ABVC 0
- ICCC 0
- Target Price
- ABVC N/A
- ICCC N/A
- AVG Volume (30 Days)
- ABVC 70.7K
- ICCC 19.9K
- Earning Date
- ABVC 11-03-2025
- ICCC 11-13-2025
- Dividend Yield
- ABVC N/A
- ICCC N/A
- EPS Growth
- ABVC N/A
- ICCC N/A
- EPS
- ABVC N/A
- ICCC 0.20
- Revenue
- ABVC $797,916.00
- ICCC $28,274,756.00
- Revenue This Year
- ABVC $735.18
- ICCC N/A
- Revenue Next Year
- ABVC N/A
- ICCC N/A
- P/E Ratio
- ABVC N/A
- ICCC $31.40
- Revenue Growth
- ABVC 56.52
- ICCC 21.75
- 52 Week Low
- ABVC $0.40
- ICCC $3.38
- 52 Week High
- ABVC $5.48
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- ABVC 46.98
- ICCC 49.27
- Support Level
- ABVC $2.75
- ICCC $5.90
- Resistance Level
- ABVC $3.03
- ICCC $6.30
- Average True Range (ATR)
- ABVC 0.15
- ICCC 0.28
- MACD
- ABVC -0.01
- ICCC -0.00
- Stochastic Oscillator
- ABVC 32.79
- ICCC 38.37
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.